Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen

Hofmann, A.; Heim, Richard R.; Brack, Alexander; Kobel, H.; Frey, A.; Ott, H.; Petrzilka, Th.; Troxler, F.

doi:10.1002/hlca.19590420518

Cited by 204 publications

(113 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This material stimulated the pioneering and exciting studies of Gordon Wasson and his wife Valentina, mycologist Roger Heim of the Museum Cryptogamie in Paris, and Dr. Albert Hofmann, biochemist with Sandoz in Basel to focus their scientific studies on the ritual use, taxonomy and chemistry of these mushrooms (Wasson, 1957;Hofmann et al, 1959).…”

Section: Background 11 a Historical Perspectivementioning

confidence: 99%

See 1 more Smart Citation

Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids

Andersson¹,

Gry²,

Kristinsson³

2009

TemaNord

View full text Add to dashboard Cite

Section: Background 11 a Historical Perspectivementioning

confidence: 99%

“…Keller´s reaction Preparative isolation of psilocybin and psilocin and weighing of the compounds Hofmann et al, 1958aHofmann et al, , 1959 Methanol, according to Hofmann et al, 1958a LC, cellulose McCawley et al, 1962 Methanol, shaking for 8 h, repeated two times PC Acidified DMAB Semiquantitative results.…”

Section: Lc Cellulosementioning

confidence: 99%

Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids

Andersson¹,

Gry²,

Kristinsson³

2009

TemaNord

View full text Add to dashboard Cite

“…Recognising that its psychoactive properties were likely to be of interest both to psychiatrists and academics, it was marketed in 1947 under the trade name 'Delysid' and made freely available to those interested in researching its properties. Hofmann also isolated and synthesised the active component of psilocybe 'magic' mushrooms, psilocybin, in 1958 (Hofmann et al, 1959). This was marketed by Sandoz under the brand name 'Indocybin'.…”

Section: Introductionmentioning

confidence: 99%

Psychiatry & the psychedelic drugs. Past, present & future

2018

View full text Add to dashboard Cite

a b s t r a c tThe classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and mescaline, were used extensively in psychiatry before they were placed in Schedule I of the UN Convention on Drugs in 1967. Experimentation and clinical trials undertaken prior to legal sanction suggest that they are not helpful for those with established psychotic disorders and should be avoided in those liable to develop them. However, those with so-called 'psychoneurotic' disorders sometimes benefited considerably from their tendency to 'loosen' otherwise fixed, maladaptive patterns of cognition and behaviour, particularly when given in a supportive, therapeutic setting. Pre-prohibition studies in this area were sub-optimal, although a recent systematic review in unipolar mood disorder and a meta-analysis in alcoholism have both suggested efficacy. The incidence of serious adverse events appears to be low. Since 2006, there have been several pilot trials and randomised controlled trials using psychedelics (mostly psilocybin) in various non-psychotic psychiatric disorders. These have provided encouraging results that provide initial evidence of safety and efficacy, however the regulatory and legal hurdles to licensing psychedelics as medicines are formidable. This paper summarises clinical trials using psychedelics pre and post prohibition, discusses the methodological challenges of performing good quality trials in this area and considers a strategic approach to the legal and regulatory barriers to licensing psychedelics as a treatment in mainstream psychiatry.

show abstract

“…«Les Teochichimèques possédaient une grande connaissance des herbes et des racines. . (20,22,23) (Fig. 2).…”

Section: Des Drogues Magiques Des Aztèques à La Thérapie Psycholytiqueunclassified